All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
The latest global regulatory news, changes and updates affecting medical devices and technologies, including: Johnson & Johnson, Takeda Pharmaceutical.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Arch Therapeutics, Cytosorbents.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Apollo Endosurgery, Atricure, Eos imaging, Kolon Tissuegene, Piranha Medical, Pluristem, Predictive Biotech, Predictive Technology, Rethink My Health, Scworx, Shockwave Medical, Staar Surgical.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Allen Technologies, Alphatec Holdings, Auburn University, Avacta Group, Biobot Analytics, Biodesix, Chembio Diagnostics, Cryo Innovations, Cytiva, Genomoncology, Hai Kang, HPC-AI, Integra Lifesciences, Intuitive, JMA, Labcorp, Myomo, Myriad, Nanomix, National Supercomputing Centre, Novacyt Group, Organovo, Pacific Biosciences of California, Pharmacyte, Phunware, Ping An Good Doctor, Predictive Laboratories, Resolution Medical, Roji Health Intelligence, Tarveda Therapeutics, Vitalhub, Wellgistics.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Algernon, Arch, Arcturus, Ascletis, Astrazeneca, Athersys, Beigene, Can-Fite, Fennec, Hope, Merck, Predictive Biotech, Proteostasis, Ridgeback.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: 89bio, Alimera, Cannabics, Celltrion, CNS, Coherus, Connectyx, Enlivex, Fulcrum, Gilead, La Jolla, Medgenome, Ocular, Orgenesis, Pluristem, Redhill, Tamir, Thermogenesis, Vaxil, WPD.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: 89bio, Aslan, Bausch Health, Kolon, Lilly, Nextcure, Prolynx.
Physicians who perform a variety of device implant procedures face a difficult choice in determining whether a patient should be treated. A new article in the Journal of the American College of Cardiology (JACC) recommends that patients who ordinarily would be candidates for surgical aortic valve replacement (SAVR) might instead be referred for the transcatheter alternative.
RSS
